Article: Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research.

BETHESDA, Md., March 16 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of six abstracts for poster presentations at the 100th annual meeting of AACR taking place from April 20-24, 2009, in Denver, Colorado.

 
  The following posters will be presented: 
 
  1. Lutterbuese, R. et al. (2009). Highly efficient lysis of KRAS- and 
 BRAF-mutated human colon cancer cells by T cell-engaging BiTE 
 antibodies derived from anti-EGFR antibodies cetuximab and panitumumab. 
 AACR Annual Meeting 2009, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!